Determining the associations of GFAP with an existing tau marker and neurodegenerative metric, together with brain amyloid, could be helpful toward establishing a better understanding of the potential multi-faceted role of astrocytosis as well as determining if GFAP serves as a viable blood-based biomarker in AD. This evidence concerns the gene MAPT and Alzheimer disease.